Show simple item record

dc.contributor.authorAksenov, Alexander V.
dc.contributor.authorSmirnov, Alexander N.
dc.contributor.authorMagedov, Igor V.
dc.contributor.authorReisenauer, Mary R.
dc.contributor.authorAksenov, Nicolai A.
dc.contributor.authorAksenova, Inna V.
dc.contributor.authorPendleton, Alexander L.
dc.contributor.authorNguyen, Gina
dc.contributor.authorJohnston, Robert K.
dc.contributor.authorRubin, Michael
dc.contributor.authorDe Carvalho, Annelise
dc.contributor.authorKiss, Robert
dc.contributor.authorMathieu, Véronique
dc.contributor.authorLefranc, Florence
dc.contributor.authorCorrea, Jaime
dc.contributor.authorCavazos, David A.
dc.contributor.authorBrenner, Andrew J.
dc.contributor.authorBryan, Brad A.
dc.contributor.authorRogelj, Snezna
dc.contributor.authorKornienko, Alexander
dc.contributor.authorFrolova, Liliya V.
dc.date.accessioned2017-04-18T17:31:19Z
dc.date.available2017-04-18T17:31:19Z
dc.date.issued2015-03-12
dc.identifier.citationAksenov, A. V., Smirnov, A. N., Magedov, I. V., Reisenauer, M. R., Aksenov, N. A., Aksenova, I. V., … Frolova, L. V. (2015). Activity of 2-Aryl-2-(3-indolyl)acetohydroxamates Against Drug-Resistant Cancer Cells. Journal of Medicinal Chemistry, 58(5), 2206–2220. http://doi.org/10.1021/jm501518yen_US
dc.identifier.urihttp://hdl.handle.net/1808/23727
dc.description.abstractMany types of tumor, including glioma, melanoma, non-small cell lung, esophageal, head and neck cancer, among others, are intrinsically resistant to apoptosis induction and poorly responsive to current therapies with proapoptotic agents. In addition, tumors often develop multi-drug resistance based on the cellular efflux of chemotherapeutic agents. Thus, novel anticancer agents capable of overcoming these intrinsic or developed tumor resistance mechanisms are urgently needed. We describe a series of 2-aryl-2-(3-indolyl)acetohydroxamic acids, which are active against apoptosis- and multidrug-resistant cancer cells as well as glioblastoma neurosphere stem-like cell cultures derived from patients. Thus, the described compounds serve as a novel chemical scaffold for the development of potentially highly effective clinical cancer drugs.en_US
dc.publisherAmerican Chemical Societyen_US
dc.rightsThis document is the Accepted Manuscript version of a Published Work that appeared in final form in the Journal of Medicinal Chemistry, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see http://dx.doi.org/10.1021/jm501518y.en_US
dc.titleActivity of 2-Aryl-2-(3-indolyl)acetohydroxamates Against Drug-Resistant Cancer Cellsen_US
dc.typeArticleen_US
kusw.kuauthorRubin, Michael
kusw.kudepartmentChemistryen_US
dc.identifier.doi10.1021/jm501518yen_US
dc.identifier.orcidhttps://orcid.org/0000-0002-1668-9311
kusw.oaversionScholarly/refereed, author accepted manuscripten_US
kusw.oapolicyThis item meets KU Open Access policy criteria.en_US
dc.rights.accessrightsopenAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record